|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500115539 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-28 22:04:03 |
|
注册时间: Date of Registration: |
2025-12-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中青年乳腺癌患者家庭功能提升方案构建及效果评价 |
|
Public title: |
Construction and Effect Evaluation of Family Function Improvement Program for Young and Middle-aged Breast Cancer Patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中青年乳腺癌患者家庭功能提升方案构建及效果评价 |
|
Scientific title: |
Construction and Effect Evaluation of Family Function Improvement Program for Young and Middle-aged Breast Cancer Patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王影 |
研究负责人: |
王影 |
|
Applicant: |
Wang Ying |
Study leader: |
Wang Ying |
|
申请注册联系人电话: Applicant telephone: |
+86 13855880903 |
研究负责人电话: Study leader's telephone: |
+86 558 3010819 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
36163913@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
36163913@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽省阜阳市颍州区三清路501号 |
研究负责人通讯地址: |
三清路501号阜阳市人民医院 |
|
Applicant address: |
No. 501, Sanqing Road, Yingzhou District, Fuyang City, Anhui Province |
Study leader's address: |
501 Sanqing Road, Yingzhou District, Fuyang City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
阜阳市人民医院 |
||
|
Applicant's institution: |
Fuyang People's Hospital |
||
|
研究负责人所在单位: |
阜阳市人民医院 |
||
|
Affiliation of the Leader: |
Fuyang People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
医伦理审查[2025]71号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
阜阳市人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Fuyang People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-05-28 00:00:00 |
||
|
伦理委员会联系人: |
黄珍 |
||
|
Contact Name of the ethic committee: |
Huang Zhen |
||
|
伦理委员会联系地址: |
三清路501号阜阳市人民医院 |
||
|
Contact Address of the ethic committee: |
501 Sanqing Road, Yingzhou District, Fuyang City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 558 3010032 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
15055842006@163.com |
|
研究实施负责(组长)单位: |
阜阳市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fuyang People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
三清路501号阜阳市人民医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
501 Sanqing Road, Yingzhou District, Fuyang City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2024年度安徽省卫生健康科研项目立项 |
||||||||||||||||||||||
|
Source(s) of funding: |
Anhui Provincial Health Research Project Approved in 2024 |
||||||||||||||||||||||
|
Target disease: |
Young and middle-aged breast cancer |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本研究拟在基于成人依恋理论及前期横断面调查、质性研究的基础上,进一步构建中青年乳腺癌患者家庭功能提升方案,并探讨临床应用效果。目前国内对乳腺癌家庭功能主要集中在现状调查,缺乏具体实施方案的研究,因此本研究拟根据成人依恋理论制定干预方案,以期提升中青年乳腺癌的家庭功能水平,提高其生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on adult attachment theory and previous cross-sectional surveys and qualitative research, this study aims to construct a family function enhancement program for young and middle-aged breast cancer patients and explore its clinical application effectiveness. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合《中国抗癌协会乳腺癌诊治指南与规范(2021年版)》中,行一侧或双侧乳房切除术后的乳腺癌患者; 2.年龄15~44周岁; 3.思维清晰,与调查人员沟通良好; 4.患者知情同意并自愿参与本研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients with breast cancer who have undergone unilateral or bilateral mastectomy, as defined in the "Chinese Anti-Cancer Association Guidelines and Standards for Breast Cancer Diagnosis and Treatment (2021 Edition)"; 2.Age 15 to 44 years old; 3.Clear thinking and good communication with investigators; 4.The patient gave informed consent and voluntarily participated in this study; |
||||||||||||||||||||||
|
排除标准: |
1.伴随其他恶性肿瘤者; 2.伴随严重的心肺功能异常者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Associated with other malignant tumors; 2.Patients with severe cardiopulmonary dysfunction. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-01 00:00:00至 To 2028-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-01-04 00:00:00 至 To 2028-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文发表中占展现结果;投稿前数据上报科研部。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The paper publication accounts for the presentation results; data must be submitted to the Research Department prior to submission. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据收集的形式:一期横断面调查,二期现场搜集。数据专人管理,保护患者隐私。使用数据时采用脱敏处理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection form: Phase I cross-sectional survey, Phase II field collection.Data is managed by designated personnel to protect patient privacy. Desensitization is applied when using data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |